Blood Biomarkers for the Management of Mild Traumatic Brain Injury in Clinical Practice

• Published in: Clinical chemistry (Baltimore, Md.) Md.), 2024-08, Vol.70 (8), p.1023-1036
• Main Authors: Oris, Charlotte, Kahouadji, Samy, Bouvier, Damien, Sapin, Vincent
• Format: Article
• Language: English
• Subjects: Biomarkers - blood; Brain Concussion - blood; Brain Concussion - diagnosis; Glial Fibrillary Acidic Protein - blood; Humans; S100 Calcium Binding Protein beta Subunit - blood; Tomography, X-Ray Computed; Ubiquitin Thiolesterase - blood
• ISSN: 0009-9147; 1530-8561; 1530-8561
• DOI: 10.1093/clinchem/hvae049

Despite the use of validated guidelines in the management of mild traumatic brain injury (mTBI), processes to limit unnecessary brain scans are still not sufficient and need to be improved. The use of blood biomarkers represents a relevant adjunct to identify patients at risk for intracranial injury requiring computed tomography (CT) scan. Biomarkers currently recommended in the management of mTBI in adults and children are discussed in this review. Protein S100 beta (S100B) is the best-documented blood biomarker due to its validation in large observational and interventional studies. Glial fibrillary acidic protein (GFAP) and ubiquitin carboxyterminal hydrolase L-1 (UCH-L1) have also recently demonstrated their usefulness in patients with mTBI. Preanalytical, analytical, and postanalytical performance are presented to aid in their interpretation in clinical practice. Finally, new perspectives on biomarkers and mTBI are discussed. In adults, the inclusion of S100B in Scandinavian and French guidelines has reduced the need for CT scans by at least 30%. S100B has significant potential as a diagnostic biomarker, but limitations include its rapid half-life, which requires blood collection within 3 h of trauma, and its lack of neurospecificity. In 2018, the FDA approved the use of combined determination of GFAP and UCH-L1 to aid in the assessment of mTBI. Since 2022, new French guidelines also recommend the determination of GFAP and UCH-L1 in order to target a larger number of patients (sampling within 12 h post-injury) and optimize the reduction of CT scans. In the future, new cut-offs related to age and promising new biomarkers are expected for both diagnostic and prognostic applications.